Sonnet BioTherapeutics Reports Fiscal Year 2024 Financial Results and Provides Corporate Update
Provided By GlobeNewswire
Last update: Dec 17, 2024
Continued progress with both clinical trials of lead program, SON-1010, for solid tumors and Platinum-Resistant Ovarian Cancer (PROC)
Executed licensing agreement to support initiation of a Phase 2 clinical trial of SON-080 in Diabetic Peripheral Neuropathy (DPN)
Read more at globenewswire.comNASDAQ:SONN (2/21/2025, 8:00:02 PM)
1.44
+0.01 (+0.7%)
Find more stocks in the Stock Screener
